Key facts
- Addition Therapeutics’s last known valuation is $26.0M (Sep 2021).
- It has raised $106.5M across 1 recorded rounds; the latest was Early Stage VC ($28.0M) in Dec 2025.
- Notable investors include University of California, Gates Foundation, Osage University Partners, SR One Capital Management, Abingworth — 11 tracked in total.
- Addition Therapeutics has filed 1 Form D with the SEC, most recently Dec 2025 ($28.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Addition Therapeutics
Funding rounds
1 roundsAbout Addition Therapeutics
Operator of a genomic medicine platform designed to advance effective treatment for people impacted by chronic and rare diseases. The company offers an all-RNA, non-viral, LNP-based PRINT platform, enabling patients with chronic and rare diseases to receive safer, durable, one-time genetic therapies.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2021
- Employees
- 50
- Website
- additiontx.com/
- Ownership
- Privately Held (backing)
Addition Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Addition Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Addition Therapeutics in its N-PORT filings yet. We sweep new filings monthly.